ARROWHEAD PHARMACEUTICALS, INC. (ARWR) /
The cash flow of ARROWHEAD PHARMACEUTICALS, INC. over the past 10 years
Chart ARROWHEAD PHARMACEUTICALS, INC.: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, ARROWHEAD PHARMACEUTICALS, INC.'s operating cash flow was $179.55M and its capital expenditures $22.67M, leaving free cash flow of $156.89M. Free cash flow was above zero in 3 of the 10 years shown. It ranged from -$604.32M in fiscal 2024 to $161.03M in fiscal 2019. Capital expenditures were highest in fiscal 2023, at $176.74M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Sep 30, 2025 | $179.55M | $22.67M | $156.89M |
| 2024ended Sep 30, 2024 | -$462.85M | $141.47M | -$604.32M |
| 2023ended Sep 30, 2023 | -$153.89M | $176.74M | -$330.63M |
| 2022ended Sep 30, 2022 | -$136.13M | $52.78M | -$188.91M |
| 2021ended Sep 30, 2021 | $171.31M | $23.57M | $147.75M |
| 2020ended Sep 30, 2020 | -$95.8M | $11.95M | -$107.75M |
| 2019ended Sep 30, 2019 | $173.03M | $12M | $161.03M |
| 2018ended Sep 30, 2018 | -$47.22M | $1.42M | -$48.64M |
| 2017ended Sep 30, 2017 | -$23.94M | $7.92M | -$31.86M |
| 2016ended Sep 30, 2016 | -$64.43M | $3.86M | -$68.29M |
Fiscal years as ARROWHEAD PHARMACEUTICALS, INC. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on ARROWHEAD PHARMACEUTICALS, INC.
- The revenue of ARROWHEAD PHARMACEUTICALS, INC.
- The profitability of ARROWHEAD PHARMACEUTICALS, INC.
- The debt of ARROWHEAD PHARMACEUTICALS, INC.
- All of ARROWHEAD PHARMACEUTICALS, INC.'s financials, charted
Companies of a similar size
- VICRVICOR CORPORATION
- ADCAGREE REALTY CORPORATION
- OSKOshkosh Corporation
- WLKWestlake Corporation
- CTVACorteva, Inc.
Not investment advice. This page shows what ARROWHEAD PHARMACEUTICALS, INC. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.